Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 Biomarker disease BEFREE Patients with IDH wild type anaplastic astrocytoma and glioblastoma had a significantly shorter median PFS (19.3 months vs. NR, p = 0.001) and median OS (43.5 months vs NR, p = 0.007) than those with IDH mutated grade III anaplastic astrocytoma and oligodendroglioma. 31371189 2019
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 GeneticVariation disease BEFREE For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype. 30878754 2019
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 GeneticVariation disease BEFREE An important underlying observation was that patients with anaplastic astrocytomas (AA) without IDH mutation had a clinical course similar to that of patients with glioblastomas (GBM). 31623667 2019
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 GeneticVariation disease BEFREE In the 2016 WHO classification of diffuse glioma, the diagnosis of an (anaplastic) oligodendroglioma requires the presence of both an IDH mutation (mt) and 1p/19q codeletion, whereas (anaplastic) astrocytoma are divided in IDH wild-type and IDHmt tumors. 30072066 2018
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 GeneticVariation disease BEFREE Diffuse astrocytoma (DA), anaplastic astrocytoma (AA), and glioblastoma (GBM) are defined by the World Health Organization (WHO) based on IDH-mutational status. 28110298 2017
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 Biomarker disease BEFREE Today, the diagnosis of anaplastic oligodendroglioma requires the presence of both IDH-mt and 1p/19q co-deletion, whereas anaplastic astrocytoma is divided into IDH wild-type ( IDH-wt) and IDH-mt tumors. 28640702 2017
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 GeneticVariation disease BEFREE The R132H mutation in IDH1 was found in 60.5% (23/38) of patients in the AA cohort (Groups 2 and 4) and 20.0% (13/65) of patients from our GBM cohort (Groups 3 and 5), whereas all patients with ODG (Group 1) had a mutation either in IDH1 (n = 62) or IDH2 (n = 3). 28851427 2017
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 Biomarker disease BEFREE The majority of glioblastomas develop rapidly with a short clinical history (primary glioblastoma IDH wild-type), whereas secondary glioblastomas progress from diffuse astrocytoma or anaplastic astrocytoma. 26443480 2016
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 GeneticVariation disease BEFREE In contrast, high expression of PROX1 protein predicted shorter survival in the group of patients with IDH-mutant anaplastic astrocytomas and secondary glioblastomas. 27626492 2016
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 GeneticVariation disease BEFREE IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. 25962792 2015
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 GeneticVariation disease BEFREE This is the first report of the detection of an identical IDH2 mutation in multiple tissues and TP53 mutation in anaplastic astrocytoma in a patient with Maffucci syndrome. 24344754 2014
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 GeneticVariation disease BEFREE Anaplastic oligoastrocytoma and anaplastic astrocytoma patients with IDH gene mutation showed similar prognosis with anaplastic oligodendroglioma patients with wild-type IDH gene. 24149775 2014
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 Biomarker disease ORPHANET The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. 24993250 2014
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 Biomarker disease ORPHANET Anaplastic oligoastrocytoma and anaplastic astrocytoma patients with IDH gene mutation showed similar prognosis with anaplastic oligodendroglioma patients with wild-type IDH gene. 24149775 2014
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 Biomarker disease ORPHANET Moving toward molecular classification of diffuse gliomas in adults. 23109653 2012
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 GeneticVariation disease BEFREE Therefore, IDH mutation would be most useful when assessing prognosis of patients with grade 3 glioma with intact 1p/19q; anaplastic astrocytomas account for most of these grade 3 gliomas. 22136423 2012
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 Biomarker disease ORPHANET Molecular classification of low-grade diffuse gliomas. 21075857 2010
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 Biomarker disease ORPHANET Molecular diagnostics of gliomas: state of the art. 20714900 2010
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 GeneticVariation disease BEFREE Mutations of the IDH1 or IDH2 genes were significantly associated with improved outcome in patients with anaplastic astrocytomas. 19765000 2009
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 Biomarker disease ORPHANET IDH1 and IDH2 mutations in gliomas. 19228619 2009
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.400 Biomarker disease ORPHANET We found 165 IDH1 (72.7%) and 2 IDH2 mutations (0.9%) in 227 diffuse astrocytomas WHO grade II, 146 IDH1 (64.0%) and 2 IDH2 mutations (0.9%) in 228 anaplastic astrocytomas WHO grade III, 105 IDH1 (82.0%) and 6 IDH2 mutations (4.7%) in 128 oligodendrogliomas WHO grade II, 121 IDH1 (69.5%) and 9 IDH2 mutations (5.2%) in 174 anaplastic oligodendrogliomas WHO grade III, 62 IDH1 (81.6%) and 1 IDH2 mutations (1.3%) in 76 oligoastrocytomas WHO grade II and 117 IDH1 (66.1%) and 11 IDH2 mutations (6.2%) in 177 anaplastic oligoastrocytomas WHO grade III. 19554337 2009